Mink presents agent-797 clinical activity in immune-compromised transplant patient with severe ards at ats annual meeting

New york, may 22, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agent-797 in a complex case of severe acute respiratory distress (ards) at the american thoracic society (ats) annual meeting. these translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ards.
ARDS Ratings Summary
ARDS Quant Ranking